ProKidney shows strong Phase 2 CKD data, FDA support, and cash runway, with key readouts ahead despite single-asset risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback